Member Info for Hurst10

Perhaps you can answer me, since 9/23 - one placing and a podcast with CC, do we have a proper analytic research note written covering Avacta?

The answer is simply a question of rating and skill set and the recent appointment of the joint house broker, will carry much more gravitas both as a MM and research and will work better with the US houses post It IPO listing.

Agree, though Copenhagen office is purely because of Brexit and domestic FCA rules.

However Copenhagen buy side have strong exposure to NYSE/ Nasdaq equities via usual houses in NY, so will be introduced to Avacta Nasdaq listed.

I have often wondered if some of you actually understand how a house broker / MM runs his book.

However , You will soon work out why AVCT /CC were in such a hurry to have a UK broker office based in NY, as advertised by the CEO, plenty of corporate events/ newsflow ahead of us and hence Institutions increasing their presence prior to US IPO with Nasdaq valuation and Global US houses introducing AVCT therapeutics to leading specialist funds .

Keep buying!

From the broker's updated website:

Panmure Liberum North America

Our American office enables investors based in North America to get access to the markets at the same time and with identical hands-on service as our European clients.

That means seamless access to the original and provocative research ideas delivered by our team of analysts.

+ the house have got three new hires for NY.

Healthcare broker/ analyst will be where the company is, ie. London

NY when pre IPO roadshow takes place.

You will soon found out why the newly appointed joint house broker have been 60p on the offer, no wish to sell shares just yet!

Watch how our new NY based Broker with London MM is 60 offered and going north . Oppenheimer life sciences conference ongoing, Precision Medicine name of the game.

More conferences to follow with AVCT participating and talk about.

Meanwhile more activity in the sector, Avacta next ?

AbbVie is betting over $2.1 billion on Xilio Therapeutics' tumour-activated immunotherapy platform, marking a shift from its recent focus on neurology deals toward expanding its oncology pipeline. The collaboration, announced Wednesday, sent Xilio's shares soaring over 113% in pre-market trading.

The deal includes $52 million upfront, with $10 million as an equity investment. Xilio will also be eligible for up to approximately $2.1 billion in total contingent payments for option-related fees and milestones plus tiered royalties.

With CIBM Group a leading ASEAN bank and one of the region's foremost corporate advisors ,having doubled their shareholding in Avacta, one could off course speculate that the bank were dealing/acting in advisory/custodian role for South Korean LG Chem Life Sciences ( LG Group) who previously back in 2022 renewed it's license agreement with Avacta and has exclusive rights to develop and sell Avacta's Affimer therapeutics worldwide, which could earn Avacta $55mill in milestone payments for each new product developed by LG Chem.

UBS ,another investment bank , also double their shareholding in Avacta.

Plenty of events in the Healthcare sector over the next month or so, Oppenheimer 35th Annual Heathcare life science conference starting today, much M&A and IPO activity in the sector to look forward over the next couple of weeks and news from Avacta as well.

Interesting to see that Panmure ( the new broker ) was 40-60 on the book.

Clearly not interested in selling!!

Gucci owner Kering SA reported fourth-quarter earnings that showed a modest improvement following a prolonged downturn in the luxury market that rippled through Asia and the West in recent years. Some Wall Street analysts are asking if the worst is over.

Kering reported a 12% drop in fourth-quarter revenues to 4.39 billion euros—just slightly above Bloomberg Consensus's forecast of 4.24 billion euros. Analysts had expected revenues for the quarter to slide by around 13.3%.

CIMB hldgs and UBS both influential and busy investment banks and buying/increasing holdings during same period.

Upcoming IPO on Nasdaq could have both houses on the book along with Jefferies and Goldmans, global coverage.

- Swiss pharmaceutical company Novartis (LON:0QLR) (SIX:NOVN) announced on Tuesday that it has entered into an agreement to purchase biopharma firm Anthos Therapeutics.

The deal, which could amount to as much as $3.1 billion, is set to be finalized in the first half of this year.

Meanwhile we have yet another rumoured take over deal, with

NEW YORK/FRANKFURT, Feb 10 (Reuters) - Merck KGaA (MRCG.DE), opens new tab, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics (SWTX.O), opens new tab, according to people familiar with the matter.

Stock up 35% and several conferences on its way . CC will be busy over the next 14 days.

Another conference coming up, Oppenheimer Life Science conference 11/12 February , with the usual majors attending live or " fire chat " .

And Biotech's IPO volume building momentum.

Note buy / sell split in volume since 07.00 AM NY.

Note how the phrase the company are using in the latest web cast presentation " We also discuss how AI is being leveraged to optimise patient populations."

Trust me, the company will at the upcoming US IPO roadshow apply the AI stamp and watch how Tempus will be adding premium valuation to the upcoming share price .

With recent announcement of joint broker, with a good Healthcare presence Stateside and if one look at dealings by directors, which shows one equity sale years ago by former Ceo and one by former FD last year, leaving them both still significant shareholders with options and the fact we have regular updates from the company , with a very strong positve pipeline, it would certainly be a quite shame if the company does not get to make an IPO at a valuation substantially above current levels, because post imminent and upcomming positive news flow from the company, the usual suspects from the mayors will move in with a proposal way above current price level.However Precision Medicine is the sought after area and to be able to launch an IPO at decent US valuation is the language and model Goldman Sachs and Jefferies would happily follow up on their nationwide roadshow as bookrunners. As Avacta have indicated before with current re rating of the AVA portfolio, it is a whole new game for a therapeutic Avacta only.

Patience will be rewarded in size!

Off course one could use and take advantage of the feedback from the various company slots and will no do doubt get a positive read across from the companies in the precision medicine segment.

No doubt M&A continues and hence lifts the valuation of the sector.

Excellent timing for an IPO with Avacta therapeutics and the right houses running the book!

Just to remind ourselves that we have Oppenheimer 35Th Ann healthcare Life conference next week with will give us further momentum in the Biotech sector.

With DX disposal, further AVA news flow, one would expect pre IPO momentum to step up and leading US broker ( GS ) also joining as book runner in Q2 and the precision medicine IPO of the year off to races.

Early buying from NY today!

Tempus AI moving , hedge funds now hold + 20% of the stock.

Wise move by Avacta to sign up with them last October.